Pay in 4 interest-free payments of $5.87 Learn more
Ships within 48 hours · Estimated delivery Aug 15 - Aug 20
In September 2023, the FDA added BPC-157 to its Category 2 list of bulk drug substances under its Interim Policy on Compounding, meaning 503A compounding pharmacies and 503B outsourcing facilities are barred from using it in compounded preparations
Benefits are based on preliminary research and clinical use cases
Studies show "increased energy and slight weight changes within the first few weeks" with more substantial changes following
Dealing with cancer treatment is tough, and knowing about supplements and therapy is key
PubMed search Related Products BPC-157 + TB-500 20mg co-lyophilised 1:1 blend for combination research BPC-157 10mg standalone, for independent BPC-157 dose-response work TB-500 10mg standalone, for independent TB-500 dose-response work KLOW 80mg BPC-157 + TB-500 + GHK-Cu + KPV (4-compound multi-pathway blend) GLOW 70mg GHK-Cu + TB-500 + BPC-157 (skin / regenerative tri-blend) BPC-157 UK Research Guide 2026 mechanism, purity standards, UK research compliance TB-500 / Thymosin Beta-4 Research Guide cell migration biology and protocol context
US$ 27.17
US$ 22.64
US$ 26.67
US$ 26.16
US$ 25.16
US$ 21.17
US$ 23.85
